"Based on our current trial enrollment and dosing pace, we estimate we will reach this milestone in the third week of November", Bourla wrote.
A man works in the packaging facility of Chinese vaccine maker Sinovac Biotech, developing an experimental coronavirus disease (COVID-19) vaccine, during a government-organized media tour in Beijing, China, September 24, 2020. That trial remains on hold in the U.S. One bright sign is that Covid-19 treatments have improved markedly, and since the cases are more spread out than before, hospitals aren't being overwhelmed.
The Food and Drug Administration (FDA), which authorizes pharmaceuticals for distribution in the United States - asked vaccine developers last week to spend two months monitoring for serious side effects after the second dose is given to trial participants.
"Maine is committed to working with the health sector and stakeholders across the state as we plan to receive and distribute a vaccine when it becomes available", said Governor Janet Mills in a statement.
Young and healthy people can get sick and possibly die of COVID-19 while spreading it among others.
However, in an updated document released Wednesday (NZ time), the US Centres for Disease Control and Prevention said that with limited supplies, it may ask some groups of people to not get the vaccine at first.
Health workers, the elderly, and other vulnerable groups would be vaccinated first - potentially leaving others to wait until 2022, she said.
Trials for a vaccine produced by AstraZeneca remain frozen by the Food and Drug Administration after a neurological issue was discovered in a trial participant in the UK.
Third, and at last, Bourla defined the company wants to have the flexibility to show that the vaccine could possibly be constantly made on the most high quality standards.
A roll out of the coronavirus vaccine is being considered for December, with sources saying that there is a "50/50" chance of the jab being available by the end of the year.
Authorities did not say how many people in the city had been given the vaccine, which comes in two doses, administered up to 28 days apart and costing a total of 400 yuan (50 Euro).
In addition to safety and efficacy, the FDA will also examine Pfizer's manufacturing operations for the vaccine. When you've sent your account email, we'll send an email with a reset code.